Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Veledimex
Price:
Purity: 99.0%
Stocking Period: 10 Day
Contact: Yang

1093130-72-3

1093130-72-3 structure

Name: Veledimex
Chemical Name: N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide
CAS Number: 1093130-72-3
Molecular Formula: C₂₇H₃₈N₂O₃
Molecular Weight: 438.60200
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2017-02-24 00:34:19
Modify Date: 2024-01-08 18:13:07
Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.

Name	N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide
Synonyms	INXN-1001 Veledimex UNII-ASU841TV0X

Description	Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Cytochrome P450 Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Cancer Research Areas >> Inflammation/Immunology
In Vivo	Veledimex generally has moderate to low oral bioavailability after a single oral administration in mice and monkeys (-56% in mice and up to 17.4% in cynomolgus monkeys) with mostly low plasma clearance (1399 and 1170 mL/h per kilogram in mice and monkeys, respectively), high volume of distribution (20271 and 9180 mL/h per kilogram in mice and monkeys, respectively), and long terminal half-lives (-10 hours in mice and -30 hours in monkeys) after intravenous administration[1]. Ad-RTS-mIL-12 + veledimex have demonstrated a dose-related increase in tumor IL-12 mRNA and IL-12 protein expression. Discontinuation of veledimex resulted in a return to baseline IL-12 mRNA and protein expression in numerous syngeneic mouse tumor models. Veledimex crosses the blood-brain-barrier in both naive and orthotopic GL-261 mice with increased brain tissue level of -6 fold observed in tumor bearing vs. normal mice. Ad-RTS-mIL-12 + veledimex demonstrate a dose-related increase in survival without significant adverse events[2].
References	[1]. Cai H, et al. Plasma Pharmacokinetics of Veledimex, a Small-Molecule Activator Ligand for a Proprietary Gene Therapy Promoter System, in Healthy Subjects. Clin Pharmacol Drug Dev. 2017 May;6(3):246-257. [2]. John A. Barrett, INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA. Neuro Oncol. 2015 Nov; 17(Suppl 5): v113.

Molecular Formula	C₂₇H₃₈N₂O₃
Molecular Weight	438.60200
Exact Mass	438.28800
PSA	62.13000
LogP	6.45120
Storage condition	2-8℃

1093130-72-3	755013-59-3
1093131-03-3	1158522-08-7
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	110979-04-9
849349-65-1